Patients with atherothrombotic conditions, acute coronary syndromes, or undergoing percutaneous interventions
Clopidogrel therapy, including standard and high-dose regimens, and alternative antiplatelet agents
Clopidogrel resistance, primarily driven by inadequate active metabolite generation due to genetic or metabolic factors, can be potentially managed by utilizing higher doses or alternative P2Y12 inhibitors.
Clopidogrel, a drug belonging to the thienopyridine class of antiplatelet agents, has been utilized either as a standalone medication or in combination with aspirin for averting vascular complications in patients afflicted with atherothrombotic conditions. The selective and irreversible blockade of the P2Y12 receptor by clopidogrel makes it a potent inhibitor of platelet activation and aggregation. In patients with acute coronary syndromes or undergoing percutaneous interventions, combining clopidogrel with aspirin is a crucial approach to antiplatelet therapy. The aim of this review article is to investigate the factors that contribute to clopidogrel resistance, mechanisms involved in clopidogrel resistance, evaluate it through laboratory methods and clinical implications of clopidogrel resistance. Additionally, the article explores the clinical importance of Clopidogrel Resistance and its correlation with harmful cardiovascular events. The paper concludes by proposing potential solutions to this resistance and suggesting the usage of alternative antiplatelet from the new generation.
Building similarity graph...
Analyzing shared references across papers
Loading...
B. V. Raghavendra
JSS Academy of Higher Education and Research
J. Lakshmi
Acharya N. G. Ranga Agricultural University
K. Naga Anusha
World Journal of Advanced Research and Reviews
Building similarity graph...
Analyzing shared references across papers
Loading...
Raghavendra et al. (Thu,) studied this question.
synapsesocial.com/papers/6a1b8347d426719c76abc6bb — DOI: https://doi.org/10.30574/wjarr.2023.19.2.1408